MontenegroTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.58 (0.56–0.6)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.18 (0.084–0.31) 29 (13–50)
Incidence  (includes HIV+TB) 0.13 (0.11–0.15) 21 (18–24)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.03 (0.02–0.04)
         
Case detection, all forms (%) 87 (77–99)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0 (0–5.7) 40 (5.3–85)
MDR-TB cases among notified pulmonary
TB cases
0 (0–5) 4 (0–8)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 63   7
Pulmonary, clinically diagnosed 27   2
Extrapulmonary 13   1
       
Total new and relapse 113    
Previously treated, excluding relapses 0    
Total cases notified 113    
Among 113 new and relapse cases:
0 (0%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 63 (100%) 5 (50%) 68
Laboratory-confirmed RR-/MDR-TB cases     2
Patients started on MDR-TB treatment ***     2
TB/HIV 2014 Number (%)
TB patients with known HIV status 94 (83)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (87) 119
Previously treated cases registered in 2013   1
HIV-positive TB cases, all types, registered in 2013 (100) 2
RR-/MDR-TB cases started on second-line treatment in 2012 (100) 1
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 8.0
Drug susceptibility testing (per 5 million population) 8.0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-05 Data: www.who.int/tb/data